tetano
Editor, Senior Moderator
Vaccine. 2018 Jul 12. pii: S0264-410X(18)30894-6. doi: 10.1016/j.vaccine.2018.06.053. [Epub ahead of print]
[h=1]Novel influenza vaccine M2SR protects against drifted H1N1 and H3N2 influenza virus challenge in ferrets with pre-existing immunity.[/h] Hatta Y[SUP]1[/SUP], Boltz D[SUP]2[/SUP], Sarawar S[SUP]3[/SUP], Kawaoka Y[SUP]4[/SUP], Neumann G[SUP]5[/SUP], Bilsel P[SUP]6[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Current influenza vaccines do not provide effective protection against heterologous influenza viruses. The ability of the novel M2SR influenza vaccine to protect against drifted influenza viruses was evaluated in na?ve ferrets and in ferrets with pre-existing immunity to influenza. In na?ve ferrets, M2SR provided similar protection against drifted challenge viruses as the comparator vaccine, FluMist?. However, in ferrets with pre-existing immunity, M2SR provided superior protection than FluMist in two model systems. In the first model, ferrets were infected with influenza A H1N1pdm and influenza B viruses to mimic the diverse influenza exposure in humans. The pre-infected ferrets, seropositive to H1N1pdm and influenza B but seronegative to H3N2, were then vaccinated with H3N2 M2SR or monovalent H3N2 FluMist virus (A/Brisbane/10/2007, clade 1) and challenged 6 weeks later with a drifted H3N2 virus (clade 3C.2a). Antibody titers to Brisbane/10/2007 were higher in M2SR vaccinated ferrets than in FluMist vaccinated ferrets in the pre-infected ferrets whereas the opposite was observed in na?ve ferrets. After challenge with drifted H3N2 virus, M2SR provided superior protection than FluMist monovalent vaccine. In the second model, the impact of homologous pre-existing immunity upon vaccine-induced protection was evaluated. Ferrets, pre-infected with H1N1pdm virus, were vaccinated 90 days later with H1N1pdm M2SR or FluMist monovalent vaccine and challenged 6 weeks later with a pre-pandemic seasonal H1N1 virus, A/Brisbane/59/2007 (Bris59). While cross-reactive serum IgG antibodies against the Bris59 HA were detected after vaccination, anti-Bris59 hemagglutination inhibition antibodies were only detected post-challenge. M2SR provided better protection against Bris59 challenge than FluMist suggesting that homologous pre-existing immunity affected FluMist virus to a greater degree than M2SR. These results suggest that the single replication intranasal M2SR vaccine provides effective protection against drifted influenza A viruses not only in na?ve ferrets but also in those with pre-existing immunity in contrast to FluMist viruses.
[h=4]KEYWORDS:[/h] Drifted; Hemagglutination inhibition; Heterosubtypic immunity; Intranasal; Live influenza; M2-deficient; Pre-existing immunity; Single replication
PMID: 30007825 DOI: 10.1016/j.vaccine.2018.06.053
Free full text
[h=1]Novel influenza vaccine M2SR protects against drifted H1N1 and H3N2 influenza virus challenge in ferrets with pre-existing immunity.[/h] Hatta Y[SUP]1[/SUP], Boltz D[SUP]2[/SUP], Sarawar S[SUP]3[/SUP], Kawaoka Y[SUP]4[/SUP], Neumann G[SUP]5[/SUP], Bilsel P[SUP]6[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Current influenza vaccines do not provide effective protection against heterologous influenza viruses. The ability of the novel M2SR influenza vaccine to protect against drifted influenza viruses was evaluated in na?ve ferrets and in ferrets with pre-existing immunity to influenza. In na?ve ferrets, M2SR provided similar protection against drifted challenge viruses as the comparator vaccine, FluMist?. However, in ferrets with pre-existing immunity, M2SR provided superior protection than FluMist in two model systems. In the first model, ferrets were infected with influenza A H1N1pdm and influenza B viruses to mimic the diverse influenza exposure in humans. The pre-infected ferrets, seropositive to H1N1pdm and influenza B but seronegative to H3N2, were then vaccinated with H3N2 M2SR or monovalent H3N2 FluMist virus (A/Brisbane/10/2007, clade 1) and challenged 6 weeks later with a drifted H3N2 virus (clade 3C.2a). Antibody titers to Brisbane/10/2007 were higher in M2SR vaccinated ferrets than in FluMist vaccinated ferrets in the pre-infected ferrets whereas the opposite was observed in na?ve ferrets. After challenge with drifted H3N2 virus, M2SR provided superior protection than FluMist monovalent vaccine. In the second model, the impact of homologous pre-existing immunity upon vaccine-induced protection was evaluated. Ferrets, pre-infected with H1N1pdm virus, were vaccinated 90 days later with H1N1pdm M2SR or FluMist monovalent vaccine and challenged 6 weeks later with a pre-pandemic seasonal H1N1 virus, A/Brisbane/59/2007 (Bris59). While cross-reactive serum IgG antibodies against the Bris59 HA were detected after vaccination, anti-Bris59 hemagglutination inhibition antibodies were only detected post-challenge. M2SR provided better protection against Bris59 challenge than FluMist suggesting that homologous pre-existing immunity affected FluMist virus to a greater degree than M2SR. These results suggest that the single replication intranasal M2SR vaccine provides effective protection against drifted influenza A viruses not only in na?ve ferrets but also in those with pre-existing immunity in contrast to FluMist viruses.
[h=4]KEYWORDS:[/h] Drifted; Hemagglutination inhibition; Heterosubtypic immunity; Intranasal; Live influenza; M2-deficient; Pre-existing immunity; Single replication
PMID: 30007825 DOI: 10.1016/j.vaccine.2018.06.053
Free full text